Symbols / GLUE $16.03 -1.96%
GLUE Chart
About
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.22B |
| Enterprise Value | 713.59M | Income | 20.95M | Sales | 181.54M |
| Book/sh | 3.98 | Cash/sh | 6.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 147 | IPO | — |
| P/E | 50.09 | Forward P/E | -9.24 | PEG | — |
| P/S | 6.73 | P/B | 4.03 | P/C | — |
| EV/EBITDA | 42.37 | EV/Sales | 3.93 | Quick Ratio | 6.45 |
| Current Ratio | 6.54 | Debt/Eq | 16.34 | LT Debt/Eq | — |
| EPS (ttm) | 0.32 | EPS next Y | -1.73 | EPS Growth | — |
| Revenue Growth | 38.50% | Earnings | 2026-03-17 | ROA | 1.37% |
| ROE | 9.28% | ROIC | — | Gross Margin | 28.08% |
| Oper. Margin | -258.26% | Profit Margin | 11.54% | Shs Outstand | 76.24M |
| Shs Float | 46.37M | Short Float | 16.55% | Short Ratio | 9.73 |
| Short Interest | — | 52W High | 25.77 | 52W Low | 3.50 |
| Beta | 1.64 | Avg Volume | 1.60M | Volume | 1.16M |
| Target Price | $33.17 | Recom | Strong_buy | Prev Close | $16.35 |
| Price | $16.03 | Change | -1.96% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$33.17
Mean price target
2. Current target
$16.03
Latest analyst target
3. DCF / Fair value
$11.47
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$16.03
Low
$30.00
High
$37.00
Mean
$33.17
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-14 | reit | Piper Sandler | Overweight → Overweight | $37 |
| 2026-01-08 | main | Wells Fargo | Overweight → Overweight | $30 |
| 2026-01-08 | main | Guggenheim | Buy → Buy | $34 |
| 2025-12-16 | up | Wells Fargo | Equal-Weight → Overweight | $22 |
| 2025-11-07 | main | Wells Fargo | Equal-Weight → Equal-Weight | $13 |
| 2025-03-21 | main | Wells Fargo | Equal-Weight → Equal-Weight | $10 |
| 2025-03-21 | main | Wedbush | Outperform → Outperform | $17 |
| 2025-03-12 | init | LifeSci Capital | — → Outperform | $19 |
| 2024-12-19 | down | Wells Fargo | Overweight → Equal-Weight | $11 |
| 2024-09-12 | reit | Wedbush | Outperform → Outperform | $11 |
| 2024-08-12 | main | Wells Fargo | Overweight → Overweight | $17 |
| 2024-06-28 | reit | Piper Sandler | Overweight → Overweight | $16 |
| 2024-05-22 | reit | Wedbush | Outperform → Outperform | $11 |
| 2024-02-15 | init | Wedbush | — → Outperform | $11 |
| 2023-10-19 | main | JP Morgan | Overweight → Overweight | $11 |
| 2023-08-11 | reit | Credit Suisse | Neutral → Neutral | $11 |
| 2023-05-12 | reit | Credit Suisse | Neutral → Neutral | $11 |
| 2023-03-17 | main | Credit Suisse | — → Neutral | $11 |
| 2023-01-03 | up | Wells Fargo | Equal-Weight → Overweight | $19 |
| 2022-10-13 | init | UBS | — → Buy | $22 |
- Heart risk, prostate cancer: Monte Rosa data and $345M war chest - Stock Titan ue, 17 Mar 2026 11
- Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance ue, 17 Mar 2026 12
- Does Monte Rosa (GLUE)–J&J ERLEADA Supply Deal Reframe GLUE’s MYC Degrader Investment Story? - simplywall.st ue, 17 Mar 2026 00
- Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q4 Revenue $2.8M - marketscreener.com ue, 17 Mar 2026 11
- GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Zacks Investment Research hu, 08 Jan 2026 08
- Monte Rosa rises on J&J collaboration for cancer therapy trial (GLUE:NASDAQ) - Seeking Alpha Mon, 16 Mar 2026 11
- Monte Rosa Therapeutics (GLUE) extends cash runway to 2029 after $345M raise - Stock Titan ue, 17 Mar 2026 11
- Monte Rosa Therapeutics (GLUE) expected to beat earnings estimates: Can the stock move higher? - MSN hu, 12 Mar 2026 17
- Monte Rosa Therapeutics (GLUE) Likely to Surpass Earnings Forecasts: Will the Share Price Rise? - Bitget hu, 12 Mar 2026 17
- Why Did GLUE Stock Surge Over 50% In Premarket Today? - Stocktwits Wed, 07 Jan 2026 08
- Monte Rosa Therapeutics (NASDAQ: GLUE) touts MGD pipeline and major Novartis, Roche deals - Stock Titan ue, 17 Mar 2026 11
- Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans - Yahoo Finance ue, 17 Mar 2026 12
- GLUE SEC Filings - Monte Rosa Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan Mon, 16 Mar 2026 19
- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ? - Yahoo Finance Wed, 29 Oct 2025 07
- Advanced prostate cancer trial tests MRT-2359 with J&J’s ERLEADA - Stock Titan Mon, 16 Mar 2026 11
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 139 | 2496 | — | Sale at price 17.96 per share. | DUNN EDMUND | Officer | — | 2026-03-04 00:00:00 | D |
| 1 | 5466 | 97974 | — | Sale at price 17.92 per share. | WARMUTH MARKUS M.D. | Chief Executive Officer | — | 2026-03-02 00:00:00 | D |
| 2 | 25700 | 464886 | — | Sale at price 17.50 - 18.10 per share. | DUNN EDMUND | Officer | — | 2026-03-02 00:00:00 | D |
| 3 | 25700 | 344637 | — | Conversion of Exercise of derivative security at price 13.41 per share. | DUNN EDMUND | Officer | — | 2026-03-02 00:00:00 | D |
| 4 | 9189 | 179161 | — | Sale at price 19.50 per share. | JANKU FILIP | Officer | — | 2026-02-23 00:00:00 | D |
| 5 | 5466 | 128373 | — | Sale at price 23.24 - 24.57 per share. | WARMUTH MARKUS M.D. | Chief Executive Officer | — | 2026-01-07 00:00:00 | D |
| 6 | 3155 | 47861 | — | Sale at price 15.17 per share. | TOWNSON SHARON | Officer | — | 2026-01-05 00:00:00 | D |
| 7 | 10135 | 153748 | — | Sale at price 15.17 per share. | WARMUTH MARKUS M.D. | Chief Executive Officer | — | 2026-01-05 00:00:00 | D |
| 8 | 3155 | 47861 | — | Sale at price 15.17 per share. | JANKU FILIP | Officer | — | 2026-01-05 00:00:00 | D |
| 9 | 3155 | 47861 | — | Sale at price 15.17 per share. | NICKSON PHILIP | Officer | — | 2026-01-05 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 87.36K | -217.77K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -73.41M | -136.05M | -108.76M | -70.59M |
| TotalUnusualItems | 416.00K | -1.04M | 119.00K | -162.00K |
| TotalUnusualItemsExcludingGoodwill | 416.00K | -1.04M | 119.00K | -162.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -72.70M | -135.35M | -108.50M | -73.96M |
| ReconciledDepreciation | 8.12M | 6.22M | 3.75M | 2.13M |
| EBITDA | -72.99M | -137.09M | -108.64M | -70.75M |
| EBIT | -81.11M | -143.31M | -112.38M | -72.88M |
| NetInterestIncome | 10.57M | 9.33M | 3.76M | 46.00K |
| InterestIncome | 10.57M | 9.33M | 3.76M | 46.00K |
| NormalizedIncome | -73.03M | -134.53M | -108.62M | -73.80M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -72.70M | -135.35M | -108.50M | -73.96M |
| TotalExpenses | 156.73M | 143.31M | 112.38M | 72.88M |
| TotalOperatingIncomeAsReported | -81.11M | -143.31M | -112.38M | -72.88M |
| DilutedAverageShares | 61.51M | 51.40M | 47.23M | 25.00M |
| BasicAverageShares | 61.51M | 51.40M | 47.23M | 25.00M |
| DilutedEPS | -1.18 | -2.63 | -2.30 | -2.96 |
| BasicEPS | -1.18 | -2.63 | -2.30 | -2.96 |
| DilutedNIAvailtoComStockholders | -72.70M | -135.35M | -108.50M | -73.96M |
| NetIncomeCommonStockholders | -72.70M | -135.35M | -108.50M | -73.96M |
| NetIncome | -72.70M | -135.35M | -108.50M | -73.96M |
| NetIncomeIncludingNoncontrollingInterests | -72.70M | -135.35M | -108.50M | -73.96M |
| NetIncomeContinuousOperations | -72.70M | -135.35M | -108.50M | -73.96M |
| TaxProvision | 2.57M | 338.00K | 0.00 | |
| PretaxIncome | -70.13M | -135.01M | -108.50M | -73.96M |
| OtherIncomeExpense | 416.00K | -1.04M | 119.00K | -1.12M |
| OtherNonOperatingIncomeExpenses | -960.00K | |||
| SpecialIncomeCharges | 0.00 | 24.00K | 109.00K | 0.00 |
| GainOnSaleOfPPE | 0.00 | 24.00K | 109.00K | 0.00 |
| GainOnSaleOfSecurity | 416.00K | -1.06M | 10.00K | -162.00K |
| NetNonOperatingInterestIncomeExpense | 10.57M | 9.33M | 3.76M | 46.00K |
| InterestIncomeNonOperating | 10.57M | 9.33M | 3.76M | 46.00K |
| OperatingIncome | -81.11M | -143.31M | -112.38M | -72.88M |
| OperatingExpense | 156.73M | 143.31M | 112.38M | 72.88M |
| ResearchAndDevelopment | 121.56M | 111.27M | 85.06M | 57.16M |
| SellingGeneralAndAdministration | 35.17M | 32.04M | 27.32M | 15.73M |
| GeneralAndAdministrativeExpense | 35.17M | 32.04M | 27.32M | 15.73M |
| OtherGandA | 13.02M | 12.39M | 11.94M | 6.24M |
| SalariesAndWages | 22.15M | 19.65M | 15.39M | 9.48M |
| TotalRevenue | 75.62M | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 75.62M | 0.00 | 0.00 | 0.00 |
| Line Item | 2022-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 122.27K | |||
| OrdinarySharesNumber | 61.51M | 50.14M | 49.32M | 46.54M |
| ShareIssued | 61.51M | 50.14M | 49.45M | 46.54M |
| TotalDebt | 42.72M | 46.04M | 47.00M | 0.00 |
| TangibleBookValue | 222.94M | 179.25M | 271.41M | 347.51M |
| InvestedCapital | 222.94M | 179.25M | 271.41M | 347.51M |
| WorkingCapital | 220.49M | 189.62M | 250.32M | 332.03M |
| NetTangibleAssets | 222.94M | 179.25M | 271.41M | 347.51M |
| CapitalLeaseObligations | 42.72M | 46.04M | 47.00M | 0.00 |
| CommonStockEquity | 222.94M | 179.25M | 271.41M | 347.51M |
| TotalCapitalization | 222.94M | 179.25M | 271.41M | 347.51M |
| TotalEquityGrossMinorityInterest | 222.94M | 179.25M | 271.41M | 347.51M |
| StockholdersEquity | 222.94M | 179.25M | 271.41M | 347.51M |
| GainsLossesNotAffectingRetainedEarnings | -3.36M | -2.72M | -1.75M | -2.02M |
| OtherEquityAdjustments | -3.36M | -2.72M | -1.75M | -2.02M |
| RetainedEarnings | -438.59M | -365.89M | -230.54M | -122.03M |
| AdditionalPaidInCapital | 664.87M | 547.86M | 503.70M | 471.57M |
| CapitalStock | 6.00K | 5.00K | 5.00K | 5.00K |
| CommonStock | 6.00K | 5.00K | 5.00K | 5.00K |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 215.80M | 124.50M | 70.98M | 18.81M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 58.85M | 77.91M | 45.41M | 2.18M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 0.00 | 0.00 | 0.00 |
| EmployeeBenefits | 3.70M | 2.71M | 1.53M | 2.18M |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 3.70M | 2.71M | 1.53M | 2.18M |
| NonCurrentDeferredLiabilities | 16.15M | 32.32M | 0.00 | |
| NonCurrentDeferredRevenue | 16.15M | 32.32M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 39.00M | 42.88M | 43.87M | 0.00 |
| LongTermCapitalLeaseObligation | 39.00M | 42.88M | 43.87M | 0.00 |
| CurrentLiabilities | 156.95M | 46.59M | 25.57M | 16.64M |
| OtherCurrentLiabilities | 3.35M | 1.67M | 5.02M | 840.00K |
| CurrentDeferredLiabilities | 117.23M | 17.68M | 0.00 | |
| CurrentDeferredRevenue | 117.23M | 17.68M | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 3.71M | 3.16M | 3.13M | |
| CurrentCapitalLeaseObligation | 3.71M | 3.16M | 3.13M | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 8.22M | 7.59M | 5.62M | 4.30M |
| PayablesAndAccruedExpenses | 24.43M | 16.49M | 11.80M | 11.49M |
| CurrentAccruedExpenses | 7.21M | 5.34M | 3.94M | 4.94M |
| Payables | 17.21M | 11.15M | 7.86M | 6.56M |
| AccountsPayable | 17.21M | 11.15M | 7.86M | 6.56M |
| TotalAssets | 438.73M | 303.75M | 342.39M | 366.33M |
| TotalNonCurrentAssets | 61.29M | 67.54M | 66.50M | 17.66M |
| OtherNonCurrentAssets | 4.98M | 4.93M | 4.60M | 5.34M |
| NetPPE | 56.31M | 62.61M | 61.91M | 12.32M |
| AccumulatedDepreciation | -20.36M | -12.24M | -6.25M | -2.70M |
| GrossPPE | 76.68M | 74.86M | 68.16M | 15.03M |
| Leases | 22.39M | 20.89M | 2.66M | 1.12M |
| ConstructionInProgress | 64.00K | 924.00K | 12.01M | 852.00K |
| OtherProperties | 51.87M | 50.89M | 52.60M | 12.31M |
| MachineryFurnitureEquipment | 2.35M | 2.15M | 887.00K | 742.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 377.44M | 236.21M | 275.89M | 348.67M |
| OtherCurrentAssets | 5.12M | 3.29M | 4.44M | 2.60M |
| RestrictedCash | 0.00 | 960.00K | 0.00 | |
| PrepaidAssets | 2.60M | |||
| Receivables | 173.00K | 505.00K | 7.66M | 0.00 |
| OtherReceivables | 173.00K | 505.00K | 7.66M | |
| CashCashEquivalentsAndShortTermInvestments | 372.15M | 232.41M | 262.83M | 346.07M |
| OtherShortTermInvestments | 147.90M | 104.31M | 207.91M | 0.00 |
| CashAndCashEquivalents | 224.25M | 128.10M | 54.91M | 346.07M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 38.01M | -62.84M | -105.38M | -69.09M |
| RepurchaseOfCapitalStock | -641.00K | -116.00K | ||
| IssuanceOfCapitalStock | 944.00K | 0.00 | 20.05M | 380.75M |
| CapitalExpenditure | -3.99M | -19.04M | -12.91M | -9.73M |
| EndCashPosition | 229.12M | 132.68M | 60.19M | 351.41M |
| BeginningCashPosition | 132.68M | 60.19M | 351.41M | 42.86M |
| ChangesInCash | 96.44M | 72.49M | -291.22M | 308.55M |
| FinancingCashFlow | 98.89M | 27.49M | 20.47M | 377.56M |
| CashFlowFromContinuingFinancingActivities | 98.89M | 27.49M | 20.47M | 377.56M |
| NetOtherFinancingCharges | 47.00M | -116.00K | -364.00K | -3.34M |
| ProceedsFromStockOptionExercised | 51.59M | 27.61M | 775.00K | 149.00K |
| NetPreferredStockIssuance | 0.00 | 143.00M | ||
| PreferredStockIssuance | 0.00 | 143.00M | ||
| NetCommonStockIssuance | 303.00K | -116.00K | 20.05M | 237.75M |
| CommonStockPayments | -641.00K | -116.00K | ||
| CommonStockIssuance | 944.00K | 0.00 | 20.05M | 237.75M |
| InvestingCashFlow | -44.45M | 88.80M | -219.22M | -9.65M |
| CashFlowFromContinuingInvestingActivities | -44.45M | 88.80M | -219.22M | -9.65M |
| NetInvestmentPurchaseAndSale | -40.46M | 107.78M | -206.42M | 0.00 |
| SaleOfInvestment | 189.90M | 210.93M | 178.00M | 0.00 |
| PurchaseOfInvestment | -230.36M | -103.15M | -384.42M | 0.00 |
| NetPPEPurchaseAndSale | -3.99M | -18.98M | -12.80M | -9.65M |
| SaleOfPPE | 0.00 | 62.00K | 109.00K | 79.00K |
| PurchaseOfPPE | -3.99M | -19.04M | -12.91M | -9.73M |
| OperatingCashFlow | 42.00M | -43.80M | -92.47M | -59.36M |
| CashFlowFromContinuingOperatingActivities | 42.00M | -43.80M | -92.47M | -59.36M |
| ChangeInWorkingCapital | 91.40M | 72.47M | -2.13M | 6.29M |
| ChangeInOtherWorkingCapital | 82.22M | 60.18M | -107.00K | 1.11M |
| ChangeInPayablesAndAccruedExpense | 10.44M | 9.31M | 287.00K | 5.88M |
| ChangeInAccruedExpense | 4.18M | 3.56M | 1.03M | 6.59M |
| ChangeInPayable | 6.25M | 5.76M | -744.00K | -706.00K |
| ChangeInAccountPayable | 6.25M | 5.76M | -744.00K | -706.00K |
| ChangeInPrepaidAssets | -1.59M | 1.08M | -2.13M | -704.00K |
| ChangeInReceivables | 332.00K | 1.90M | -187.00K | 0.00 |
| OtherNonCashItems | 4.81M | 960.00K | ||
| StockBasedCompensation | 18.13M | 16.67M | 11.66M | 5.20M |
| AmortizationOfSecurities | -2.95M | -3.91M | -1.95M | 0.00 |
| DepreciationAmortizationDepletion | 8.12M | 6.22M | 3.75M | 2.13M |
| DepreciationAndAmortization | 8.12M | 6.22M | 3.75M | 2.13M |
| Depreciation | 8.12M | 6.22M | 3.75M | 2.13M |
| OperatingGainsLosses | 107.00K | -109.00K | 17.00K | |
| GainLossOnInvestmentSecurities | 131.00K | |||
| GainLossOnSaleOfPPE | 0.00 | -24.00K | -109.00K | 17.00K |
| NetIncomeFromContinuingOperations | -72.70M | -135.35M | -108.50M | -73.96M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GLUE
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|